1. United States
2. Tenn.
3. Letter

The FDA needs to reject the Pharmacy Compounding Advisory Committee's recommendation to add BPC-157, KPV, TB-500, and MOTS-c to the list of substances compounding pharmacies can produce. The committee voted against the agency's own career scientists, who flagged a fundamental problem: there is no universally accepted chemical formula for these peptides. FDA official Russell Wesdyk put it plainly — "We've never faced a problem of, What is it?" You cannot evaluate the safety of a substance you cannot even define. Eight of the panel members voting yes were appointed under Secretary Kennedy, and six of those eight run clinics that sell peptides. That is a staggering conflict of interest. Committee member Dr. Elizabeth Rebello invoked the Hippocratic oath in opposition, arguing that approving substances without knowing whether they cause harm is indefensible. She's right. The final decision rests with the FDA through a formal rule proposal, which means there is still time to stop this. Do your job and make sure the agency follows its scientists, not its market.